|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RAD51 is known to be a crucial regulator for DNA damage repair and has been reported to influence cell radio-resistance in cancers, including in CC.
|
31190335 |
2020 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In eukaryotes Rad51 is the recombinase capable of carrying out essential steps including strand invasion, homology search on the sister chromatid and strand exchange.
|
31748913 |
2020 |
|
Prostate carcinoma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The WRN protein along with ATM, BRCA1, BRCA2, and RAD51 among others, comprise a DNA repair system by homologous recombination, and its alterations are associated with forms of hereditary PCa.
|
31831298 |
2020 |
|
cervical cancer
|
0.050 |
Biomarker
|
disease |
BEFREE |
Finally, rescue assays indicated that miR-4429 promoted CC cell radio-sensitivity through RAD51.
|
31190335 |
2020 |
|
Malignant tumor of cervix
|
0.040 |
Biomarker
|
disease |
BEFREE |
Finally, rescue assays indicated that miR-4429 promoted CC cell radio-sensitivity through RAD51.
|
31190335 |
2020 |
|
Cervix carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Finally, rescue assays indicated that miR-4429 promoted CC cell radio-sensitivity through RAD51.
|
31190335 |
2020 |
|
Ataxia Telangiectasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These have resulted in higher resolution structural models of the signalling proteins ATM (ataxia telangiectasia mutated), and ATR (ataxia telangiectasia and Rad3-related protein), along with various structures of Rad51.
|
31748913 |
2020 |
|
Diffuse Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The differential gene expression signature revealed enrichment of inflammatory markers, as previously observed in MZL, while tMZL and de novo DLBCL were enriched for extracellular matrix proteins such as collagen and fibronectin, vascular development protein PDGFRβ, DNA repair protein RAD51, and oncogenic secrete protein Wnt11.
|
31804739 |
2020 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
In breast cancer cells, PTEN inhibition represses nuclear translocation of breast cancer susceptibility 1 (BRCA1) and Rad51; this impairs DNA repair resulting in an accumulation of damaged DNA, which contributes to cell senescence.
|
30521029 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Both FBC and OBC induced oxidative DNA damage and time-dependent DNA repair responses with increased gene expressions of breast cancer susceptibility protein 1 (<i>brca1</i>), recombination protein A paralog B (<i>rad51b</i>), methyl methanesulfonate-sensitivity protein 22-like and tonsoku-like (<i>mms22l</i>).
|
30931099 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
UALCAN portal was used to evaluate the expression of RAD51 and survival probability based on tumor stage, subtype, and race in breast cancer patients.
|
31492187 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
RAD51 recombinase (RAD51), a key protein of homologous recombination, was detected to interact with BReast CAncer genes 2 (BRCA2).
|
31506496 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that Jab1 association with Rad51 plays an important role in cellular response to chemotherapy in breast cancer.
|
30244171 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interestingly, loss of SIM2s was shown to result in failure of RAD51 to localize to sites of replication stress in both breast cancer cell lines and primary mammary epithelial cells.
|
31775907 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The BRCA1-BRCA2-RAD51 axis is essential for homologous recombination repair (HRR) and is frequently disrupted in breast cancers.
|
30554948 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Germline DNA from 1054 BRCA-mutation-negative Hispanic women with hereditary BC (BC diagnosed at age <51 years, bilateral BC, breast and ovarian cancer, or BC diagnosed at ages 51-70 years with ≥2 first-degree or second-degree relatives who had BC diagnosed at age <70 years), 312 local controls, and 887 multiethnic cohort controls was sequenced and analyzed for 12 known and suspected, high-penetrance and moderate-penetrance cancer susceptibility genes (ataxia telangiectasia mutated [ATM], breast cancer 1 interacting protein C-terminal helicase 1 [BRIP1], cadherin 1 [CDH1], checkpoint kinase 2 [CHEK2], nibrin [NBN], neurofibromatosis type 1 [NF1], partner and localizer of BRCA2 [PALB2], phosphatase and tensin homolog [PTEN], RAD51 paralog 3 [RAD51C], RAD51D, serine/threonine kinase 11 [STK11], and TP53).
|
31206626 |
2019 |
|
Fanconi Anemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Isolated lymphocytes from the patient were hypersensitive to chromosomal breakage induced by the DNA cross-linking agent, mitomycin C. Our detailed phenotypic analysis of the RAD51-associated atypical FA revealed clinical manifestations from the diverse population and a consistent FA phenotype characterized by chromosome instability, intellectual disability, radial ray abnormality, and microcephaly, but not bone marrow failure.
|
30907510 |
2019 |
|
Fanconi Anemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Deficiency in several of the classical human RAD51 paralogs [RAD51B, RAD51C, RAD51D, XRCC2 and XRCC3] is associated with cancer predisposition and Fanconi anemia.
|
31584931 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that Jab1 association with Rad51 plays an important role in cellular response to chemotherapy in breast cancer.
|
30244171 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In breast cancer cells, PTEN inhibition represses nuclear translocation of breast cancer susceptibility 1 (BRCA1) and Rad51; this impairs DNA repair resulting in an accumulation of damaged DNA, which contributes to cell senescence.
|
30521029 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
RAD51 recombinase (RAD51), a key protein of homologous recombination, was detected to interact with BReast CAncer genes 2 (BRCA2).
|
31506496 |
2019 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
UALCAN portal was used to evaluate the expression of RAD51 and survival probability based on tumor stage, subtype, and race in breast cancer patients.
|
31492187 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interestingly, loss of SIM2s was shown to result in failure of RAD51 to localize to sites of replication stress in both breast cancer cell lines and primary mammary epithelial cells.
|
31775907 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Germline DNA from 1054 BRCA-mutation-negative Hispanic women with hereditary BC (BC diagnosed at age <51 years, bilateral BC, breast and ovarian cancer, or BC diagnosed at ages 51-70 years with ≥2 first-degree or second-degree relatives who had BC diagnosed at age <70 years), 312 local controls, and 887 multiethnic cohort controls was sequenced and analyzed for 12 known and suspected, high-penetrance and moderate-penetrance cancer susceptibility genes (ataxia telangiectasia mutated [ATM], breast cancer 1 interacting protein C-terminal helicase 1 [BRIP1], cadherin 1 [CDH1], checkpoint kinase 2 [CHEK2], nibrin [NBN], neurofibromatosis type 1 [NF1], partner and localizer of BRCA2 [PALB2], phosphatase and tensin homolog [PTEN], RAD51 paralog 3 [RAD51C], RAD51D, serine/threonine kinase 11 [STK11], and TP53).
|
31206626 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Both FBC and OBC induced oxidative DNA damage and time-dependent DNA repair responses with increased gene expressions of breast cancer susceptibility protein 1 (<i>brca1</i>), recombination protein A paralog B (<i>rad51b</i>), methyl methanesulfonate-sensitivity protein 22-like and tonsoku-like (<i>mms22l</i>).
|
30931099 |
2019 |